Effect of polymers for aerolization properties of mannitol-based microcomposites containing meloxicam

European Polymer Journal

Volumn 49, Issue 9, 2013, Pages 2518-2527

  Pomázi, Anita ^a   Buttini, Francesca ^b   Ambrus, Rita ^a   Colombo, Paolo ^b   Szabó Révész, Piroska ^a  

^a UNIVERSITY OF SZEGED   (Hungary)

^b UNIVERSITY OF PARMA   (Italy)

Author keywords

Aerodynamic properties; Co spray drying; Meloxicam; Microcomposite; Polyvinyl alcohol; Polyvinylpirrolidone

Indexed keywords

AERODYNAMIC PROPERTIES; CO-SPRAY-DRYING; MELOXICAM; MICROCOMPOSITE; POLYVINYLPIRROLIDONE;

AERODYNAMICS; AMINO ACIDS; COMPOSITE MATERIALS; DISSOLUTION; DRUG DELIVERY; DRUG PRODUCTS; POLYOLS; POLYVINYL ALCOHOLS;

POLYMERS;

EID: 84881369362     PISSN: 00143057     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eurpolymj.2013.03.017     Document Type: Article

References (37)

1. M.P. Timsina, G.P. Martin, and C. Marriott Drug-delivery to the respiratory-tract using dry powder inhalers Int J Pharm 101 1994 1 13
2. N. Islam, and E. Gladki Dry powder inhalers (DPIs)-review of device reliability and innovation Int J Pharm 360 2008 1 11
3. I. Gonda The ascent of pulmonary drug delivery J Pharm Sci 89 2000 940 945
4. M.J. Telko, and A.J. Hickey Dry powder inhaler formulation Respir Care 50 2005 1209 1227
5. G. Buckton Characterization of small changes in the physical properties of powders of significance for dry powder inhaler formulations Adv Drug Deliver Rev 26 1997 17 27
6. A.J. Hickey Lung deposition and clearance of pharmaceutical aerosols: what can be learned from inhalation toxicology and industrial hygiene? Aerosol Sci Technol 18 2007 290 304
7. W. Wong, J. Crapper, H.K. Chan, D. Traini, and P.M. Young Pharmacopeial methodologies for determining aerodynamic mass distribution of ultra-high dose inhalers medicines J Pharm Biomed Anal 51 2010 853 857
8. European Pharmacopoeia (Ph.Eur. 7.2). Preparations for inhalation. Aerodynamic assessment of fine particles - fine particle dose and particle size distribution (Ph. Eur. Method 2.9.18); 2012.
9. Bianco S. Anti-reactive anti-asthmatic activity of non-steroidal anti-inflammatory drugs by inhalation. United States Patent 2000; 6051566.
10. Rabinowitz JD, Zaffaroni AC. Delivery on nonsteroidal antiinflammatory drugs through an inhalation route. United States Patent 2004; 6716417.
11. J. Tamaoki, J. Nakata, K. Nishimura, M. Kondo, K. Aoshiba, and K. Kawatani Effect of inhaled indomethacin in asthmatic patients taking high doses of inhaled corticosteroids J Allergy Clin Immunol 105 2000 1134 1139
12. D.E. Frust Meloxicam: selective COX-2 inhibition in clinical practice Semin Arthritis Rheum 26 1997 21 27
13. P. Luger, K. Daneck, W. Engel, G. Trummlitz, and K. Wagner Structure and physicochemical properties of meloxicam, a new NSAID Eur J Pharm Sci 4 1996 175 187
14. S. Bavbek, A.B. Dursun, E. Dursun, A. Erylmiaz, and Z. Misirligil Safety of meloxicam in aspirin-hypersensitive patients with asthma and/or nasal polyps Int Arch Allergy Immunol 142 2007 64 69
15. D. Bednarek, A. Szuster-Ciesielska, B. Zdzisinska, M. Kondracki, B. Paduch, and M. Kandefer-Szerszen The effect of steroidal and non-steroidal anti-inflammatory drugs on the cellular immunity of calves with experimentally induced local lung inflammation Vet Immunol Immunopathol 71 1999 17 28
16. Y. Tsubouchi, S. Mukai, Y. Kawahito, R. Yamada, M. Kohno, and K.I. Inoue Meloxicam inhibits the growth of non small cell lung cancer Anticancer Res 20 2000 2867 2872
17. R.F. Souza, K. Shewmake, D.G. Beer, B. Cryer, and S.J. Spechler Selective inhibition of cyclooxygenase-2 suppresses growth and induces apoptosis in human oesophageal adenocarcinoma cells Cancer Res 60 2005 5767 5772
18. H.M.M. Arafa, M.H. Abdel-Wahab, M.F. El-Shafeey, O.A. Badary, and F.M.A. Hamada Anti-fibrotic effect of meloxicam in a murine lung fibrosis model Eur J Pharmacol 564 2007 181 189
19. B. Driessen Pain: systemic and local/regional drug therapy Clin Technol Equine Pract 6 2007 135 144
20. A. Pomazi, R. Ambrus, P. Sipos, and P. Szabó-Révész Analysis of co-spray-dried meloxicam-mannitol systems containing crystalline microcomposites J Pharm Biomed Anal 56 2011 183 190
21. R. Ambrus, A. Pomázi, K. Réti-Nagy, F. Fenyvesi, M. Vecsernyés, and P. Szabó-Révész Cytotoxicity testing of carrier-based microcomposites for DPI application Pharmazie 66 2011 549 550
22. B.V. Robinson, F.M. Sullivan, J.F. Borzelleca, and S.L. Schwartz A critical review of the kinetics and toxicology of polyvinylpirrolidone (POVIDONE) 1990 Lewis Publishers, Inc. Chelsea p. 1-6
23. G. Pilcer, and K. Amighi Formulation strategy and use of excipients in pulmonary drug delivery Int J Pharm 392 2010 1 19
24. F. Buttini, A. Soltani, P. Colombo, C. Mariotti, and S.A. Jones Multilayer PVA adsorption onto hydrophobic drug substrates to engineer drug-rich microparticles Eur J Pharm Sci 33 2008 20 28
25. H.D. Smyth, and A.J. Hickey Carriers in drug powder delivery: implications for inhalation system design Am J Drug Deliver 3 2005 117 132
26. P.R. Nassab, Z.S. Tüske, P. Kása, A. Bashiri-Shahroodi, and P. Szabó-Révész Influence of work of adhesion on dissolution rate in binary solid systems J Adhes 83 2007 799 810
27. H. Adi, P.M. Young, H.K. Chan, H. Agus, and D. Traini Co-spray-dried mannitol-ciprofloxacin dry powder inhaler formulation for cystic fibrosis and chronic obstructive pulmonary disease Eur J Pharm Sci 40 2010 239 247
28. J. Raula, A. Lähde, and E.I. Kauppinen Aerosolization behavior of carrier-free l-leucine coated salbutamol sulphate powders Int J Pharm 365 2009 18 25
29. K.A. Khan The concept of dissolution efficiency J Pharm Pharmacol 27 1975 48 49
30. N.H. Anderson, M. Bauer, N. Boussac, R. Khan-Malek, P. Munden, and M. Sardaro An evaulation of fit factors and dissolution efficiency for the comparison of in vitro dissolution profiles J Pharm Biomed Anal 17 1998 811 822
31. F.O. Costa, J.J.S. Sousa, A.A.C.C. Pais, and S.J. Formosinho Comparison of dissolution profiles of Ibuprofen pellets J Control Release 89 2003 199 212
32. P.C. Seville, T.P. Learoyd, H.Y. Li, I.J. Williamson, and J.C. Birchall Amino acid-modified spray-dried powders with enhanced aerosolisation properties for pulmonary drug delivery Powder Technol 178 2007 40 50
33. L. Prota, A. Santoro, M. Bifulco, R.P. Aquino, T. Mencherini, and P. Russo Leucine enhances aerosol performance of Naringin dry powder and its activity on cystic fibrosis airway epithelial cells Int J Pharm 412 2011 8 19
34. T.M. Crowder, J.A. Rosati, J.D. Schroeter, A.J. Hickey, and T.B. Martonen Fundamental effects of particle morphology on lung delivery: predictions of Stokes' law and the particular relevance to dry powder inhaler formulation and development Pharm Res 19 2002 239 245
35. R.S.N. Campbell, A.C. Williams, M. Griemsey, and S.W. Booth Quantitative analysis of mannitol polymorphs. X-ray powder diffractometry-exploring preferred orientation effects J Pharm Biomed Anal 28 2002 1149 1159
36. A. Burger, J.O. Henck, S. Hetz, J.M. Rollinger, A.A. Weissnicht, and H. Stöttner Energy/temperature diagram and compression behaviour of the polymorphs of mannitol J Pharm Sci 89 2000 457 468
37. W.L. Hulse, R.T. Forbes, M.C. Bonner, and M. Getrost The characterization and comparison and spray dried mannitol samples Drug Dev Ind Pharm 35 2009 712 718